Focused On-demand Library for Tumor necrosis factor receptor superfamily member 18

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9Y5U5

UPID:

TNR18_HUMAN

Alternative names:

Activation-inducible TNFR family receptor; Glucocorticoid-induced TNFR-related protein

Alternative UPACC:

Q9Y5U5; B1AME1; O95851; Q5U0I4; Q9NYJ9

Background:

Tumor necrosis factor receptor superfamily member 18 (TNFRSF18), also known as the activation-inducible TNFR family receptor or glucocorticoid-induced TNFR-related protein, plays a pivotal role in immune regulation. It acts as a receptor for TNFSF18, facilitating interactions between activated T-lymphocytes and endothelial cells. This protein is crucial in regulating T-cell receptor-mediated cell death and activates NF-kappa-B via the TRAF2/NIK pathway.

Therapeutic significance:

Understanding the role of Tumor necrosis factor receptor superfamily member 18 could open doors to potential therapeutic strategies. Its involvement in T-cell regulation and NF-kappa-B activation positions it as a key target for modulating immune responses in various conditions.